Alector grants Genentech exclusive rights to develop and commercialize AL050, an investigational GCase Enzyme Replacement Therapy (ERT) enabled by Alector Brain Carrier (ABC), Alector’s proprietary blood-brain barrier delivery platform Alector to receive $100 million upfront payment, with potential
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming
Advancing the Alector Brain Carrier (ABC) blood-brain barrier platform across antibodies, enzymes, and siRNA, with AL137 advancing as Alector’s lead ABC -enabled anti-amyloid beta (Aβ) antibody program for Alzheimer’s disease (AD). Continued progress across AL064/AL164 ( ABC -enabled Tau siRNA for
Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 ( ABC -enabled antibody for Alzheimer’s disease (AD)), AL050 ( ABC -enabled GCase Enzyme Replacement Therapy for
--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC -enabled candidates, including an anti-Aβ antibody for Alzheimer’s disease (AD), a GCase enzyme replacement therapy (ERT) for